ArriVent BioPharma (AVBP) Current Assets (2023 - 2026)

ArriVent BioPharma has disclosed Current Assets across 4 years of filings, most recently posting $348.7 million for Q1 2026.

• Current Assets for Q1 2026 came in at $348.7 million, up 87.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $348.7 million (up 87.69% YoY), and the FY2025 annual result was $332.9 million, up 46.66% from the prior year.
• Current Assets came in at $348.7 million for Q1 2026 at ArriVent BioPharma, up from $332.9 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $348.7 million in Q1 2026 to a low of $160.0 million in Q4 2023.
• The 4-year median for Current Assets is $300.5 million (2024), against an average of $275.4 million.
• Across the five-year window, Current Assets tumbled 43.27% in 2025 and jumped 87.69% in 2026, its largest moves.
• ArriVent BioPharma's Current Assets stood at $160.0 million in 2023, then surged by 41.89% to $227.0 million in 2024, then soared by 46.66% to $332.9 million in 2025, then advanced by 4.75% to $348.7 million in 2026.
• The last three Current Assets figures came in at $348.7 million (Q1 2026), $332.9 million (Q4 2025), and $321.2 million (Q3 2025), per Business Quant data.